vs
EXACT SCIENCES CORP（EXAS）与FEDERAL SIGNAL CORP（FSS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是FEDERAL SIGNAL CORP的1.5倍（$878.4M vs $597.1M），FEDERAL SIGNAL CORP净利率更高（10.2% vs -9.8%，领先20.0%），FEDERAL SIGNAL CORP同比增速更快（26.5% vs 23.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $89.5M），过去两年FEDERAL SIGNAL CORP的营收复合增速更高（18.5% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
联邦信号公司是20世纪早期的美国企业，主营铁路信号设备的制造业务，总部坐落于美国纽约州奥尔巴尼市，其生产的相关信号产品在当时的美国轨道交通行业得到了广泛应用，具备一定的行业知名度。
EXAS vs FSS — 直观对比
营收规模更大
EXAS
是对方的1.5倍
$597.1M
营收增速更快
FSS
高出3.4%
23.1%
净利率更高
FSS
高出20.0%
-9.8%
自由现金流更多
EXAS
多$30.9M
$89.5M
两年增速更快
FSS
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $597.1M |
| 净利润 | $-86.0M | $60.8M |
| 毛利率 | 70.1% | 28.4% |
| 营业利润率 | -9.4% | 14.0% |
| 净利率 | -9.8% | 10.2% |
| 营收同比 | 23.1% | 26.5% |
| 净利润同比 | 90.1% | 21.6% |
| 每股收益（稀释后） | $-0.45 | $0.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFSS
| Q4 25 | $878.4M | $597.1M | ||
| Q3 25 | $850.7M | $555.0M | ||
| Q2 25 | $811.1M | $564.6M | ||
| Q1 25 | $706.8M | $463.8M | ||
| Q4 24 | $713.4M | $472.0M | ||
| Q3 24 | $708.7M | $474.2M | ||
| Q2 24 | $699.3M | $490.4M | ||
| Q1 24 | $637.5M | $424.9M |
净利润EXASFSS
| Q4 25 | $-86.0M | $60.8M | ||
| Q3 25 | $-19.6M | $68.1M | ||
| Q2 25 | $-1.2M | $71.4M | ||
| Q1 25 | $-101.2M | $46.3M | ||
| Q4 24 | $-864.6M | $50.0M | ||
| Q3 24 | $-38.2M | $53.9M | ||
| Q2 24 | $-15.8M | $60.8M | ||
| Q1 24 | $-110.2M | $51.6M |
毛利率EXASFSS
| Q4 25 | 70.1% | 28.4% | ||
| Q3 25 | 68.6% | 29.1% | ||
| Q2 25 | 69.3% | 30.0% | ||
| Q1 25 | 70.8% | 28.2% | ||
| Q4 24 | 69.0% | 28.1% | ||
| Q3 24 | 69.4% | 29.6% | ||
| Q2 24 | 69.8% | 29.4% | ||
| Q1 24 | 70.0% | 27.3% |
营业利润率EXASFSS
| Q4 25 | -9.4% | 14.0% | ||
| Q3 25 | -3.0% | 16.9% | ||
| Q2 25 | -0.3% | 17.3% | ||
| Q1 25 | -13.6% | 14.2% | ||
| Q4 24 | -122.8% | 14.9% | ||
| Q3 24 | -5.6% | 16.0% | ||
| Q2 24 | -3.8% | 16.5% | ||
| Q1 24 | -16.7% | 12.8% |
净利率EXASFSS
| Q4 25 | -9.8% | 10.2% | ||
| Q3 25 | -2.3% | 12.3% | ||
| Q2 25 | -0.1% | 12.6% | ||
| Q1 25 | -14.3% | 10.0% | ||
| Q4 24 | -121.2% | 10.6% | ||
| Q3 24 | -5.4% | 11.4% | ||
| Q2 24 | -2.3% | 12.4% | ||
| Q1 24 | -17.3% | 12.1% |
每股收益（稀释后）EXASFSS
| Q4 25 | $-0.45 | $0.99 | ||
| Q3 25 | $-0.10 | $1.11 | ||
| Q2 25 | $-0.01 | $1.16 | ||
| Q1 25 | $-0.54 | $0.75 | ||
| Q4 24 | $-4.69 | $0.80 | ||
| Q3 24 | $-0.21 | $0.87 | ||
| Q2 24 | $-0.09 | $0.99 | ||
| Q1 24 | $-0.60 | $0.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $63.7M |
| 总债务越低越好 | — | $564.6M |
| 股东权益账面价值 | $2.4B | $1.4B |
| 总资产 | $5.9B | $2.4B |
| 负债/权益比越低杠杆越低 | — | 0.41× |
8季度趋势，按日历期对齐
现金及短期投资EXASFSS
| Q4 25 | $964.7M | $63.7M | ||
| Q3 25 | $1.0B | $54.4M | ||
| Q2 25 | $858.4M | $64.7M | ||
| Q1 25 | $786.2M | $57.5M | ||
| Q4 24 | $1.0B | $91.1M | ||
| Q3 24 | $1.0B | $73.7M | ||
| Q2 24 | $946.8M | $48.6M | ||
| Q1 24 | $652.1M | $48.9M |
总债务EXASFSS
| Q4 25 | — | $564.6M | ||
| Q3 25 | — | $201.2M | ||
| Q2 25 | — | $258.3M | ||
| Q1 25 | — | $266.9M | ||
| Q4 24 | — | $204.4M | ||
| Q3 24 | — | $223.3M | ||
| Q2 24 | — | $248.8M | ||
| Q1 24 | — | $266.8M |
股东权益EXASFSS
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $3.2B | $1.1B | ||
| Q2 24 | $3.2B | $1.1B | ||
| Q1 24 | $3.1B | $1.0B |
总资产EXASFSS
| Q4 25 | $5.9B | $2.4B | ||
| Q3 25 | $5.9B | $1.9B | ||
| Q2 25 | $5.8B | $1.9B | ||
| Q1 25 | $5.7B | $1.9B | ||
| Q4 24 | $5.9B | $1.8B | ||
| Q3 24 | $6.7B | $1.7B | ||
| Q2 24 | $6.7B | $1.7B | ||
| Q1 24 | $6.4B | $1.7B |
负债/权益比EXASFSS
| Q4 25 | — | 0.41× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 0.17× | ||
| Q3 24 | — | 0.19× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.26× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $97.2M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $89.5M |
| 自由现金流率自由现金流/营收 | 13.7% | 15.0% |
| 资本支出强度资本支出/营收 | 3.6% | 1.3% |
| 现金转化率经营现金流/净利润 | — | 1.60× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $227.1M |
8季度趋势，按日历期对齐
经营现金流EXASFSS
| Q4 25 | $151.7M | $97.2M | ||
| Q3 25 | $219.9M | $61.1M | ||
| Q2 25 | $89.0M | $59.7M | ||
| Q1 25 | $30.8M | $36.7M | ||
| Q4 24 | $47.1M | $90.6M | ||
| Q3 24 | $138.7M | $68.8M | ||
| Q2 24 | $107.1M | $40.6M | ||
| Q1 24 | $-82.3M | $31.3M |
自由现金流EXASFSS
| Q4 25 | $120.4M | $89.5M | ||
| Q3 25 | $190.0M | $54.1M | ||
| Q2 25 | $46.7M | $52.4M | ||
| Q1 25 | $-365.0K | $31.1M | ||
| Q4 24 | $10.7M | $82.1M | ||
| Q3 24 | $112.6M | $60.9M | ||
| Q2 24 | $71.2M | $24.8M | ||
| Q1 24 | $-120.0M | $22.9M |
自由现金流率EXASFSS
| Q4 25 | 13.7% | 15.0% | ||
| Q3 25 | 22.3% | 9.7% | ||
| Q2 25 | 5.8% | 9.3% | ||
| Q1 25 | -0.1% | 6.7% | ||
| Q4 24 | 1.5% | 17.4% | ||
| Q3 24 | 15.9% | 12.8% | ||
| Q2 24 | 10.2% | 5.1% | ||
| Q1 24 | -18.8% | 5.4% |
资本支出强度EXASFSS
| Q4 25 | 3.6% | 1.3% | ||
| Q3 25 | 3.5% | 1.3% | ||
| Q2 25 | 5.2% | 1.3% | ||
| Q1 25 | 4.4% | 1.2% | ||
| Q4 24 | 5.1% | 1.8% | ||
| Q3 24 | 3.7% | 1.7% | ||
| Q2 24 | 5.1% | 3.2% | ||
| Q1 24 | 5.9% | 2.0% |
现金转化率EXASFSS
| Q4 25 | — | 1.60× | ||
| Q3 25 | — | 0.90× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.79× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 0.67× | ||
| Q1 24 | — | 0.61× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FSS
| Vehiclesandequipment | $403.4M | 68% |
| Parts | $66.8M | 11% |
| Publicsafetyandsecurityequipment | $62.2M | 10% |
| Rentalincome | $19.0M | 3% |
| Industrialsignalingequipment | $18.2M | 3% |
| Other | $14.9M | 2% |
| Warningsystems | $12.6M | 2% |
